Abstract
Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine
Letters in Drug Design & Discovery
Title: Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient
Volume: 8 Issue: 2
Author(s): Leonard Amaral, Marta Martins and Miguel Viveiros
Affiliation:
Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine
Abstract: Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Export Options
About this article
Cite this article as:
Amaral Leonard, Martins Marta and Viveiros Miguel, Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient, Letters in Drug Design & Discovery 2011; 8 (2) . https://dx.doi.org/10.2174/157018011794183860
DOI https://dx.doi.org/10.2174/157018011794183860 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and Biological Evaluation of Novel Heterocyclic Fluoroquinolone Citrate Conjugates as Potential Inhibitors of Topoisomerase IV: A Computational Molecular Modeling Study
Current Drug Discovery Technologies Polysaccharides to Combat Viruses (COVID-19) and Microbes: New updates
Current Molecular Pharmacology Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking
Medicinal Chemistry Recent Advances in Computer-Aided Drug Design as Applied to Anti-Influenza Drug Discovery
Current Topics in Medicinal Chemistry Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report
Current Drug Safety Advances in Drug Discovery and Development for Pediatric Tuberculosis
Mini-Reviews in Medicinal Chemistry Graph Theoretical Analysis, Insilico Modeling, Design and Synthesis of Biologically Active Pyrimidines and Quinazolines as Antimicrobial and Antitubercular Agent
Current Microwave Chemistry New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Simultaneous Detection of Drug-resistant Mutations in <i>Mycobacterium tuberculosis</i> and Determining their Role through <i>In Silico</i> Docking
Infectious Disorders - Drug Targets Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Interrelated Roles for the Aryl Hydrocarbon Receptor and Hypoxia Inducible Factor-1α in the Immune Response to Infection
Current Immunology Reviews (Discontinued) Meet Our Editorial Board Member:
Current Medicinal Chemistry Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances
Combinatorial Chemistry & High Throughput Screening Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates
Current Drug Discovery Technologies Prevalence of HIV Drug Resistance Mutation in the Northern Indian Population After Failure of the First Line Antiretroviral Therapy
Current HIV Research B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Screening of Anti-mycobacterial Phytochemical Compounds for Potential Inhibitors against Mycobacterium Tuberculosis Isocitrate Lyase
Current Topics in Medicinal Chemistry Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation
Recent Patents on Anti-Infective Drug Discovery Prediction of MicroRNA–disease Associations by Matrix Completion
Current Proteomics